Royal Bank of Canada
KRBP

Royal Bank of Canada’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Royal Bank of Canada’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 8199
2021
Q4 		$0 Buy
+1
New +$68 ﹤0.01% 8085

Other funds holding KRBP

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $706M AUM 48.92% 1-Year Est. Return

Royal Bank of Canada's KRBP Position: Q1 2022 in Review

Royal Bank of Canada sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q1 2022, closing a stake of 1 share.

Royal Bank of Canada first reported a position in KRBP in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 20 funds tracked by Wall St. Rank hold KRBP as of Q1 2022.

  • Royal Bank of Canada reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Kiromic BioPharma, Inc. Common Stock share in Q1 2022.
  • Royal Bank of Canada first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Royal Bank of Canada's Kiromic BioPharma, Inc. Common Stock position peaked at $0 in Q4 2021.
  • 20 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q1 2022.

Based on Royal Bank of Canada's 13F filing for Q1 2022, filed 16 May 2022.